Clinical trial

Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients

NCT01352208

Study summary

ClinicalTrials.gov

Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1, PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention ASP9521 Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2011-03-01

PhasePHASE1 / PHASE2

Conditions

Castrate Resistant Prostate Cancerunresolved

Interventions

ASP9521DRUG

Sponsors & collaborators

Astellas Pharma Inclead sponsor

Mapped research locations

GlasgowUnited Kingdom1 VillejuifFrance1 AntwerpBelgium1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01352208 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.